• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Inc REGN 3 Star

Last Price$422.13Day Change (%)-1.59%
Open Price$428.04Day Change ($)-6.82
Day Range421.15–431.6952-Week Range269.50–437.64

As of Fri 3/6/2015 5:00:00 PM | USD

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. Research and Markets: B-Cell Chronic Lymphocytic Leukemia Pipeline Review 2015 - 18 Companies & 29 Drug Profiles

    Research and Markets: B-Cell Chronic Lymphocytic Leukemia Pipeline Review 2015 - 18 Companies & 29 Drug Profiles

  2. Research and Markets: Hyperlipidemia Pipeline Review 2015 - Featuring 25 Leading Companies

    Research and Markets: Hyperlipidemia Pipeline Review 2015 - Featuring 25 Leading Companies

  3. Research and Markets: Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success

    Research and Markets: Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success

  4. Complexities of Eye Care Drive Strong Moats

    We see attractive growth opportunities for the ophthalmology market.

  5. Regeneron Announces Upcoming 2015 Investor Conference Presentations

    Regeneron Announces Upcoming 2015 Investor Conference Presentations

  6. UPDATE: CVS girds for battle over cholesterol drugs

    UPDATE: CVS girds for battle over cholesterol drugs

  7. CVS girds for battle over cholesterol drugs

    CVS girds for battle over cholesterol drugs

  8. T. Rowe Price Thrives Despite a Tumultuous 2013

    The firm remains on solid footing after some unexpected manager and analyst departures.

  9. T. Rowe Price Thrives Despite a Tumultuous 2013

    The firm remains on solid footing after some unexpected manager and analyst departures.

  10. A Biotech With a Growing Moat

    Regeneron's moat is widening thanks to recent clinical successes and a productive pipeline; however, investors should wait for a better price before buying.

123
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.